Prosigna is now included in International clinical practice guidelines
Managing patients with early-stage breast cancer begins with a highly accurate assessment of risk
Mastering the science of tumor biology
Prosigna uses the PAM50 gene signature to translate tumor biology into your patient's individualized prognostic score.
Achieving precise results
Advanced technology generates precise, reproducible prognostic information in local qualified laboratories.
Proven risk assessment you can trust
Prosigna reliably identifies your patient's 10-year risk of distant recurrence and intrinsic molecular subtype.
Proceed with confidence
Prosigna is indicated for use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II) or node-positive (Stage II or IIIA) early-stage breast cancer to be treated with adjuvant endocrine therapy.